Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension

Bibliography

• Galie N, Hoeper M, Humbert M, Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-63
   PubMed Web of Science ®Google Scholar
• D'Alonzo GE, Barst RJ, Ayres SM, Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9
   PubMed Web of Science ®Google Scholar
• Hassoun P, Mouthon L, Barbera J, Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54:S10-19
   PubMed Web of Science ®Google Scholar
• Chan S, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 2008;44:14-30
   PubMed Web of Science ®Google Scholar
• Bowers R, Cool C, Murphy R, Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004;169:764-9
   PubMed Web of Science ®Google Scholar
• Achcar R, Demura Y, Rai P, Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. Chest 2006;129:696-705
   PubMed Web of Science ®Google Scholar
• Badesch D, Raskob G, Elliott C, Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010;137:376-87
   PubMed Web of Science ®Google Scholar
• Budhiraja R, Tuder R, Hassoun P. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-65
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-15
   PubMed Web of Science ®Google Scholar
• Levin E. Endothelins. N Engl J Med 1995;333:356-63
   PubMed Web of Science ®Google Scholar
• Hahn A, Resink T, Scott-Burden T, Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul 1990;1:649-59
   PubMedGoogle Scholar
• Ehrenreich H, Anderson R, Fox C, Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990;172:1741-8
   PubMed Web of Science ®Google Scholar
• Rubanyi G, Botelho L. Endothelins. FASEB J 1991;5:2713-20
   PubMed Web of Science ®Google Scholar
• Schneider M, Boesen E, Pollock D. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 2007;47:731-59
   PubMed Web of Science ®Google Scholar
• Filep JG, Fournier A, Foldes-Filep E. Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors. Br J Pharmacol 1995;115:227-36
   PubMed Web of Science ®Google Scholar
• Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-83
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D, Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328(24):1732-9
   PubMedGoogle Scholar
• Cacoub P, Dorent R, Nataf P, Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 1997;33:196-200
   PubMed Web of Science ®Google Scholar
• Seo B, Oemar B, Siebenmann R, Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994;89:1203-8
   PubMed Web of Science ®Google Scholar
• Hirata Y, Emori T, Eguchi S, Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993;91:1367-73
   PubMed Web of Science ®Google Scholar
• Dupuis J, Goresky C, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996;81:1510-15
   PubMed Web of Science ®Google Scholar
• Black SM, Mata-Greenwood E, Dettman RW, Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation 2003;108:1646-54
   PubMed Web of Science ®Google Scholar
• Simonneau G, Robbins IM, Beghetti M, Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 Suppl S):S43-54
   Google Scholar
• Clozel M, Breu V, Burri K, Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993;365:759-61
   PubMed Web of Science ®Google Scholar
• Clozel M, Breu V, Gray G, Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-35
   PubMed Web of Science ®Google Scholar
• Weber C, Schmitt R, Birnboeck H, Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996;60:124-37
   PubMed Web of Science ®Google Scholar
• Dingemanse J, van Giersbergen P. Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Int J Clin Pharmacol Ther 2002;40:310-16
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903
   PubMed Web of Science ®Google Scholar
• Sitbon O, Badesch D, Channick R, Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-54
   PubMed Web of Science ®Google Scholar
• Sitbon O, McLaughlin V, Badesch D, Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005;60:1025-30
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Sitbon O, Badesch DB, Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9
   PubMed Web of Science ®Google Scholar
• Rich S, Dantzker DR, Ayres SM, Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23
   PubMed Web of Science ®Google Scholar
• Galie N, Rubin L, Hoeper M, Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-100
   PubMed Web of Science ®Google Scholar
• Degano B, Sitbon O, Savale L, Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. Chest 2010;137:1297-303
   PubMed Web of Science ®Google Scholar
• Frost A, Langleben D, Oudiz R, The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol 2005;43:36-9
   PubMed Web of Science ®Google Scholar
• Rosenzweig E, Ivy D, Widlitz A, Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:697-704
   PubMed Web of Science ®Google Scholar
• Galie N, Beghetti M, Gatzoulis M, Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54
   PubMed Web of Science ®Google Scholar
• Sitbon O, Gressin V, Speich R, Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170:1212-17
   PubMed Web of Science ®Google Scholar
• Degano B, Yaici A, Le Pavec J, Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009;33:92-8
   PubMed Web of Science ®Google Scholar
• Hoeper M, Halank M, Marx C, Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502-8
   PubMed Web of Science ®Google Scholar
• Savale L, Magnier R, Le Pavec J, Impact of pulmonary arterial hypertension specific therapy on portopulmonary hypertension. Am J Respir Crit Care Med 2010;181: abstract 3339
   Google Scholar
• Vatter H, Zimmermann M, Jung C, Effect of the novel endothelin(A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery. Clin Sci (Lond) 2002;103(Suppl 48):408S-13S
   Google Scholar
• Kingman M, Ruggiero R, Torres F. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2009;10:1847-58
   PubMed Web of Science ®Google Scholar
• Galie N, Badesch D, Oudiz R, Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-35
   PubMed Web of Science ®Google Scholar
• Galie N, Olschewski H, Oudiz RJ, Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-19
   PubMed Web of Science ®Google Scholar
• Oudiz R, Galie N, Olschewski H, Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:1971-81
   PubMed Web of Science ®Google Scholar
• McGoon M, Frost A, Oudiz R, Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009;135:122-9
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Frost A, Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Badesch D, Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-56
   PubMed Web of Science ®Google Scholar
• Lavelle A, Sugrue R, Lawler G, Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J 2009;34:770-1
   PubMed Web of Science ®Google Scholar
• Hoeper MM. Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy? Eur Respir J 2009;34:529-30
   PubMed Web of Science ®Google Scholar
• Hoeper M, Olsson K, Schneider A, Golpon H. Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy. Eur Respir J 2009;33:1518-19
   PubMed Web of Science ®Google Scholar
• Humbert M, Segal ES, Kiely DG, Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-44
   PubMed Web of Science ®Google Scholar
• Murphey LM, Hood EH. Bosentan and warfarin interaction. Ann Pharmacother 2003;37:1028-31
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Volibris: summary of product characteristics. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000839/human_med_001151.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125 [Last accessed 29 December 2010]
   Google Scholar
• van Giersbergen PL, Halabi A, Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther 2006;44:113-18
   PubMed Web of Science ®Google Scholar
• Spence R, Mandagere A, Walker G, Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 μg in healthy subjects: an open-label, single-sequence, single-centre study. Clin Drug Investig 2010;30:313-24
   PubMed Web of Science ®Google Scholar
• Montani D, O'Callaghan DS, Jais X, Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. Eur Respir Rev 2009;18:272-90
   PubMedGoogle Scholar
• O'Callaghan DS. Emerging treatments for pulmonary arterial hypertension. Clin Respir J 2008;2:132-40
   PubMedGoogle Scholar
• Barst RJ, Rubin LJ, Long WA, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996;334:296-302
   PubMed Web of Science ®Google Scholar
• Iglarz M, Binkert C, Morrison K, Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327:736-45
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Negro L, A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403
   PubMed Web of Science ®Google Scholar
• Galie N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010;31(17):2080-6
   Google Scholar
• O'Callaghan DS, Gaine SP. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med 2007;28:169-85
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, ACCF/AHA 2009 Expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American thoracic society, Inc.; and the Pulmonary hypertension association. J Am Coll Cardiol 2009;53:1573-619
   PubMed Web of Science ®Google Scholar